Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-7011a in Systemic Lupus Erythematosus With Cutaneous Lupus Erythematosus
CTR20240595Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of DS-7011a in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), sponsored by Daiichi Sankyo Co., Ltd.. Started Mar 2024; status: completed.
02
Drugs
DS-7011a
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on CTR20240595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240595.